Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADSTEM Inj. for Moderate to Severe Atopic Dermatitis
NCT07377838Phase 3Not yet recruiting
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Stem Cell Therapies
01
Overview
Phase 3, randomised, double-blind trial of ADSTEM in atopic dermatitis (AD), sponsored by EHL Bio Co., Ltd. Primary endpoint: validated Investigator's Global Assessment 0 or 1 and 2-point reduction at 16 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ADSTEM
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07377838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07377838.